Effect of Rosiglitazone, a PPAR‐γ Ligand on Haloperidol‐Induced Catalepsy
- 21 June 2013
- journal article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 19 (9) , 724-725
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of ratsToxicology Letters, 2012
- Evaluation of toxicological and antioxidant potential of Nardostachys jatamansi in reversing haloperidol-induced catalepsy in ratsInternational Journal of General Medicine, 2010
- PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s diseaseEuropean Journal of Neuroscience, 2009
- Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptorsNature, 1980
- Review of the folin phenol protein quantitation method of lowry, rosebrough, farr and randallAnalytical Biochemistry, 1979
- Involvement of the Superoxide Anion Radical in the Autoxidation of Pyrogallol and a Convenient Assay for Superoxide DismutaseEuropean Journal of Biochemistry, 1974